Design and synthesis of a novel series of HIV-1 protease inhibitors

Bioorganic and Medicinal Chemistry

Volumn 7, Issue 9, 1999, Pages 2105-2114

  Takashiro, Eiji ^a   Nakamura, Yuji ^a   Miyamoto, Shuichi ^a   Ozawa, Yuji ^a   Sugiyama, Akiko ^a   Fujimoto, Katsumi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 2 HYDROXY 4 PHENYLBUTYRIC ACID; 4 [ACETYL (1 TERT BUTYLCARBAMOYL 2 PHENYLETHYL)AMINO] 1 BENZYL 2 HYDROXYBUTYL] 3 HYDROXY 2 METHYLBENZAMIDE; [4 [ACETYL (1 TERT BUTYLCARBAMOYL 2 PHENYLETHYL)AMINO] 1 BETA NAPTHYLMETHYL 2 HYDROXYBUTYL] 3 HYDROXY 2 METHYLBENZAMIDE; ANTIVIRUS AGENT; INDINAVIR; NELFINAVIR; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHIBITION KINETICS; NONHUMAN; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

DRUG DESIGN; HIV PROTEASE INHIBITORS; MOLECULAR STRUCTURE; SPECTRUM ANALYSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032867633     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(99)00163-7     Document Type: Article

References (42)

1. Mitsuya H., Yarchoan R., Broder S. Science. 249:1990;1533.
2. Yarchoan R., Mitsuya H., Broder S. Trends in Pharmacol. Sci. 14:1993;196. and references cited therein.
3. Hellen C.U.T., Kräusslich H-G., Wimmer E. Biochemistry. 28:1989;9881.
4. For excellent reviews on HIV-1 protease inhibitors, see: Wlodawer, A.; Erickson, J. W. Annu. Rev. Biochem. 1993, 62, 543.
5. West M.L., Fairlie D.P. Trends in Pharmacol. Sci. 16:1995;67.
6. Meek T.D. J. Enzyme Inhibition. 6:1992;65.
7. Barry M., Gibbons S., Back D., Mulcahy F. Clin. Pharmacokinet. 32:1997;194.
8. Lunney E.A. Med. Chem. Res. 8:1998;352.
9. Patick A.K., Potts K.E. Clinic. Microb. Rev. 11:1998;614.
10. Boden D., Markowitz M. Antimicrob. Agents Chemother. 42:1998;2775.
11. Mimoto T., Imai J., Tanaka S., Hattori N., Takahashi O., Kisanuki S., Nagano Y., Shintani M., Hayashi H., Sakikawa H., Akaji K., Kiso Y. Chem. Pharm. Bull. 39:1991;2465.
12. Mimoto T., Imai J., Tanaka S., Hattori N., Kisanuki S., Akaji K., Kiso Y. Chem. Pharm. Bull. 39:1991;3088.
13. Mimoto T., Imai J., Kisanuki S., Enomoto H., Hattori N., Akaji K., Kiso Y. Chem. Pharm. Bull. 40:1992;2251.
14. Sakurai M., Higashida S., Sugano M., Komai T., Yagi R., Ozawa Y., Handa H., Nishigaki T., Yabe Y. Bioorg. Med. Chem. 2:1994;807.
15. Komai T., Higashida S., Sakurai M., Nitta T., Kasuya A., Miyamoto S., Yagi R., Ozawa Y., Handa H., Mohri H., Yasuoka A., Oka S., Nishigaki T., Kimura S., Shimada K., Yabe Y. Bioorg. Med. Chem. 4:1996;1365.
16. Takashiro E., Watanabe T., Nitta T., Kasuya A., Miyamoto S., Ozawa Y., Yagi R., Nishigaki T., Shibayama T., Nakagawa A., Iwamoto A., Yabe Y. Bioorg. Med. Chem. 6:1998;595.
17. Spaltenstein A., Leban J.J., Huang J.J., Reinhardt K.R, Viveros O.H., Sigafoos J., Crouch R. Tetrahedron. Lett. 37:1996;1343.
18. Kim B.M., Guare J.P., Hanifin C.M., Arford-Bickerstaff D.J., Vacca J.P., Ball R.G. Tetrahedron. Lett. 35:1994;5153.
19. Ohba T., Ikeda E., Takei H. Bioorg. Med. Chem. Lett. 6:1996;1875.
20. Hanson G.J., Lindberg T. J. Org. Chem. 50:1985;5399.
21. 2 benzamides, see: Randad, R. S.; Lubkowska, L. L.; Bhat, T. N.; Munshi, S. M.; Gulnik, S. V.; Yu, B.; Erickson, J. W. Bioorg. Med. Chem. Lett. 1995, 5, 1707.
22. Kempf D.J., Flentge C.A., Wideburg N.E., Saldivar A., Vasavanonda S., Norbeck D.W. Bioorg. Med. Chem. Lett. 5:1995;2725.
23. Kalish V.J., Tatlock J.H., Davies II J.F., Kaldor S.W., Dressmen B.A., Reich S., Pino M., Nyugen D., Appelt K., Musick L., Wu B.-W. Bioorg. Med. Chem. Lett. 5:1995;727.
24. For the reduction of α-amino ketones, see: Dondoni, A., Perrone, D. Synthesis 1993, 1162 and references cited therein.
25. For the assignment of the absolute stereochemistry based on the vicinal coupling, see: Futagawa, S.; Inui, T.; Shiba, T. Bull. Chem. Soc. Jpn. 1973, 46, 3308.
26. Rich D.H., Sun E.T.O. J. Med. Chem. 23:1980;27.
27. Cardillo G., Orena M., Sandri S., Tomasini C. Tetrahedron. 41:1985;163.
28. Houbion J.A., Miles J.A., Paton J.A. Org. Prep. Proc. Int. 11:1979;27.
29. For sulfonamide bearing compounds, see: Kim, E. E.; Baker, C. T.; Dwyer, M. D.; Murcko, M. A.; Rao, B. G.; Tung, R. D.; Navia, M. A. J. Am. Chem. Soc. 1995, 117, 1181.
30. Vazquez M.L., Bryant M.L., Clare M.C., DeCrescenzo G.A., Doherty E.M., Freskos J.N., Getman D.P., Houseman K.A., Julien J.A., Kocan G.P., Mueller R.A., Shieh H.-S., Stallings W.C., Stegeman R.A., Talley J.J. J. Med. Chem. 38:1995;581.
31. Baker C.T., Salituro F.G., Court J.J., Deininger D.D., Kim E.E., Li B., Novak P.M., Rao B.G., Pazhanisamy S., Schairer W.C., Tung R.D. Bioorg. Med. Chem. Lett. 8:1998;3631.
32. Salituro F.G., Baker C.T., Court J.J., Deininger D.D., Kim E.E., Li B., Novak P.M., Rao B.G., Pazhanisamy S., Porter M.D., Schairer W.C., Tung R.D. Bioorg. Med. Chem. Lett. 8:1998;3637.
33. For the chemistry of hydroxyethylamine, see: Shiabata, N.; Katoh, T.; Terashima, S. Tetrahedron Lett. 1997, 38, 619 and references cited therein.
34. Kaldor et al. reported that o-methyl-N-methylbenzamide exhibited a preference for an orientation in which the amide carbonyl and benzene ring were not coplanar. In this case, the ortho-methyl group might affected the conformation of sulfonamide, see: Kaldor, S. W.; Hammond, M.; Dressmen, B. A.; Fritz, J. E.; Crowell, T. A.; Hermann, R. A. Bioorg. Med. Chem. Lett. 1994, 4, 1385.
35. Kaldor et al. reported that o-methyl-N-methylbenzamide exhibited a preference for an orientation in which the amide carbonyl and benzene ring were not coplanar. In this case, the ortho-methyl group might affected the conformation of sulfonamide, see: Kaldor, S. W.; Hammond, M.; Dressmen, B. A.; Fritz, J. E.; Crowell, T. A.; Hermann, R. A. Bioorg. Med. Chem. Lett. 1994, 4, 1385.
36. For the conformation of N,N-dialkyl-benzenesulfonamides, see: 29 and references cited therein.
37. For acyclic symmetric inhibitors, see: Housur, M. V., Bhat, T. N., Kempf, D. J., Baldwin, E. T., Liu, B., Gulnik, S., Wideburg, N. E., Norbeck. D. W., Appelt, K., Erickson, J. W. J. Am. Chem. Soc. 1994, 116, 847.
38. Greer J.; Erickson, J. W.; Baldwin J.J., Varney M.D. J. Med. Chem. 37:1994;1035.
39. For carbohydrate based symmetric inhibitors, see: Zuccarello, G.; Bouzide, A.; Kvarnström, I.; Niklasson, G.; Svensson, S. C. T.; Brisander, M.; Danielsson, H.; Nillroth, U.; Karlén, A.; Hallberg, A.; Classon, B.; Samuelsson, B. J Org. Chem. 1998, 63, 4898.
40. Alterman M., Björsne M., Mühlman A., Classon B., Kvarnström I., Danielson H., Markgren P-O., Nillroth U., Unge T., Hallberg A., Samuelsson B. J Med. Chem. 41:1998;3782.
41. 2 symmetric structure, see: Rodgers, J. D.; Lam, P. Y.-S.; Johnson, B. L.; Wang, H.; Ko, S. S.; Seitz, S. P.; Trainor, G. L.; Anderson, P. S.; Kalbe, R. M.; Bacheler, L. T.; Cordova, B.; Garber, S.; Reid, C.; Wright, M. R.; Chang, C.-H.; Erickson-Viitanen, S. Chemistry & Biology 1998, 5, 597 and references cited therein.
42. Compounds 19, 21, 23, 27, 32, 33, 34, 35 and 36 could not be separated by PTLC. They were assayed as diastereomixtures.